JO3225B1 - 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 - Google Patents

6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8

Info

Publication number
JO3225B1
JO3225B1 JOP/2013/0331A JOP20130331A JO3225B1 JO 3225 B1 JO3225 B1 JO 3225B1 JO P20130331 A JOP20130331 A JO P20130331A JO 3225 B1 JO3225 B1 JO 3225B1
Authority
JO
Jordan
Prior art keywords
tarp
receptor antagonist
benzothiazol
pyrazol
pyridin
Prior art date
Application number
JOP/2013/0331A
Other languages
English (en)
Inventor
Kevin Reel Jon
Michael Witkin Jeffrey
Jaye Porter Warren
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3225B1 publication Critical patent/JO3225B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

يتعلق الاختراع الحالي بمضاد مستقبل AMPA يعتمد على TARP- ?8 له الصيغة: وأملاحه المقبولة صيدليًا، واستخداماته، وطرق تحضيره.
JOP/2013/0331A 2012-11-27 2013-11-17 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 JO3225B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27

Publications (1)

Publication Number Publication Date
JO3225B1 true JO3225B1 (ar) 2018-03-08

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0331A JO3225B1 (ar) 2012-11-27 2013-11-17 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8

Country Status (36)

Country Link
US (1) US8765960B2 (ar)
EP (1) EP2925754B1 (ar)
JP (1) JP6246227B2 (ar)
KR (1) KR101693133B1 (ar)
CN (1) CN104797578B (ar)
AP (1) AP2015008489A0 (ar)
AR (1) AR093527A1 (ar)
AU (1) AU2013352594B2 (ar)
BR (1) BR112015011200A2 (ar)
CA (1) CA2889243C (ar)
CL (1) CL2015001419A1 (ar)
CR (1) CR20150267A (ar)
CY (1) CY1118657T1 (ar)
DK (1) DK2925754T3 (ar)
DO (1) DOP2015000113A (ar)
EA (1) EA026686B1 (ar)
ES (1) ES2618260T3 (ar)
HK (1) HK1209116A1 (ar)
HR (1) HRP20170274T1 (ar)
HU (1) HUE033447T2 (ar)
IL (1) IL238831B (ar)
JO (1) JO3225B1 (ar)
MA (1) MA38126B1 (ar)
MX (1) MX356478B (ar)
MY (1) MY177721A (ar)
PE (1) PE20151728A1 (ar)
PH (1) PH12015501154A1 (ar)
PL (1) PL2925754T3 (ar)
PT (1) PT2925754T (ar)
SG (1) SG11201504164VA (ar)
SI (1) SI2925754T1 (ar)
TN (1) TN2015000200A1 (ar)
TW (2) TWI618705B (ar)
UA (1) UA114345C2 (ar)
WO (1) WO2014085153A1 (ar)
ZA (1) ZA201503733B (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
WO2016176449A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
MD3288940T2 (ro) 2015-04-29 2021-08-31 Janssen Pharmaceutica Nv Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA
EP3288945B1 (en) 2015-04-29 2019-09-18 Janssen Pharmaceutica NV Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CA2984305C (en) 2015-04-29 2021-12-28 Janssen Pharmaceutica Nv Indolone compounds and their use as ampa receptor modulators
CA3039676A1 (en) * 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv Fused bicylic pyridine compounds and their use as ampa receptor modulators
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ａｍｐａ拮抗化合物の新規製造法
EP2053041A3 (en) * 2000-06-12 2009-07-29 Eisai R&D Management Co., Ltd. 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
PT1828177E (pt) * 2004-12-17 2008-10-28 Lilly Co Eli Novos antagonistas dos receptores da mch
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
CA2739559A1 (en) * 2008-10-08 2010-04-15 Pfizer Inc. Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof
PT2385938E (pt) * 2009-01-12 2015-06-02 Pfizer Ltd Derivados de sulfonamida
US8513291B2 (en) * 2010-06-01 2013-08-20 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
JP5976011B2 (ja) * 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物

Also Published As

Publication number Publication date
CY1118657T1 (el) 2017-07-12
DK2925754T3 (en) 2017-02-20
DOP2015000113A (es) 2015-06-15
JP2016501219A (ja) 2016-01-18
ES2618260T3 (es) 2017-06-21
CN104797578A (zh) 2015-07-22
EP2925754B1 (en) 2016-12-28
UA114345C2 (uk) 2017-05-25
AU2013352594A1 (en) 2015-06-04
IL238831A0 (en) 2015-06-30
JP6246227B2 (ja) 2017-12-13
AU2013352594B2 (en) 2016-02-18
AR093527A1 (es) 2015-06-10
EP2925754A1 (en) 2015-10-07
CA2889243C (en) 2017-06-13
TW201825484A (zh) 2018-07-16
PH12015501154B1 (en) 2015-08-10
HUE033447T2 (en) 2017-11-28
CL2015001419A1 (es) 2015-10-02
PE20151728A1 (es) 2015-12-02
US20140148441A1 (en) 2014-05-29
EA026686B1 (ru) 2017-05-31
PL2925754T3 (pl) 2017-07-31
KR20150070401A (ko) 2015-06-24
CA2889243A1 (en) 2014-06-05
WO2014085153A1 (en) 2014-06-05
SG11201504164VA (en) 2015-07-30
SI2925754T1 (sl) 2017-02-28
AP2015008489A0 (en) 2015-05-31
HRP20170274T1 (hr) 2017-04-07
US8765960B2 (en) 2014-07-01
PT2925754T (pt) 2017-02-27
MY177721A (en) 2020-09-23
EA201590823A1 (ru) 2015-08-31
WO2014085153A8 (en) 2014-07-31
IL238831B (en) 2018-08-30
TWI618705B (zh) 2018-03-21
KR101693133B1 (ko) 2017-01-04
MA38126A1 (fr) 2017-03-31
PH12015501154A1 (en) 2015-08-10
CN104797578B (zh) 2016-11-23
MX2015006697A (es) 2015-08-05
MX356478B (es) 2018-05-30
ZA201503733B (en) 2017-09-27
TW201434834A (zh) 2014-09-16
MA38126B1 (fr) 2017-11-30
BR112015011200A2 (pt) 2017-07-11
CR20150267A (es) 2015-09-16
TN2015000200A1 (en) 2016-10-03
HK1209116A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
PH12015501154A1 (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
PH12019502072A1 (en) Sustained release dosage forms for a jak1 inhibitor
PH12014502169A1 (en) N-cyclylamides as nematicides
WO2012077136A3 (en) Process for the preparation of benzimidazole derivatives and its salts
MY181898A (en) Heterocyclic compounds and uses thereof
MY195209A (en) Partially Saturated Nitrogen-Containing Heterocyclic Compound
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
GB201101517D0 (en) Receptor antagonists
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
PH12015501146A1 (en) Hydantoin derivative
PH12014501760B1 (en) Method for stereoselective synthesis of 1,4-protected 9-hydroxy-5-oxo-1,4-diaza-spiro[5.5]undecanes
TN2011000588A1 (en) Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses
WO2012094437A3 (en) Nicotinic receptor non-competitive antagonists